Regional Anesthetics

Phase 1Small molecule

MMontefiore Medical Center

Regional Anesthetics is one of 37 small molecule programs targeting Hip Fracture. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hip FractureActive, not recruiting

Hip FracturePhase 1

Active, not recruiting

Competition

Competitive Landscape

116 competitors in Hip Fracture

#DrugCompanyPhaseTrials

Lovenox

Sanofi

Phase 3

1 2

Zometa

Pfizer

Phase 3

1 3

Prolia

Amgen

Phase 3

1 4

Crestor

AstraZeneca

Phase 3

1 5

Xarelto

WWim Janssens

Phase 3

2 6

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

2 7

Arixtra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

2 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

1 9

PROCRIT

WWim Janssens

Phase 3

1 10

Fosamax

OOrganon and Co

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hip Fracture1 trial

Postop Pain Control in Hip Fracture Surgery: Fascia Iliaca Compartment Block Versus Fracture Block

Withdrawn·MMontefiore Medical Center·Phase 1·NCT04335461

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Regional Anesthetics. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Regional Anesthetics compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Regional Anesthetics. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Montefiore Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMontefiore Medical Center

Regional Anesthetics

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hip Fracture1 trial

References

Drug Info

Quick Facts

Related News